GS1 Standard

New standard for investigational products answers clinical trial industry’s need for consistency

A global standard by the industry...

The new global standard is the result of an industry-led working group:

60
Representatives
37
Clinical trials organisations
9
Months of weekly meetings
Chaired by CH
Victor Dupouy,
Pfizer and Sanofi
Pharmaceutical companies,
hospitals, IT solution providers,
contract research organisations

...for the industry

Manufacturer

Packaging site

Distribution centre

Clinical site

Subject

Applicable to
blinded and unblinded trials

Global Trade Item Number (GTIN)
for unambiguous identification of investigational products and their components

No requirement to include expiration date within barcodes

Respects space
constraints of labelling small kit components

Across-the-board benefits

Benefits for suppliers

  • Quicker data compiling
  • Full supply chain traceability enabled
  • Fewer transcription errors on the backend
  • Less time spent verifying and validating data

Benefits for clinical trials sites

  • Saves time
  • Improves inventory management
  • Limits need for internal re-labelling and transcriptions
  • Easy to adopt processes that leverage the barcodes

Benefits for patients

Adopting GS1 Standard adds an element of trust at all levels of the supply chain – a trust that ultimately extends to the patients themselves.

Scope of work

This application standard focuses primarily on the identification and barcoding of investigational products from the time of kit assembly to use and, if necessary, destruction.

Investigational products include active products, comparators and placebos. Where identification of items outside of this scope, locations, patients or caregivers is required, reference is made to relevant existing GS1 standards.

At any given time, pharmaceutical companies support hundreds of clinical trials happening across the globe. Each of these trials can impact hundreds of thousands of patients and tens of thousands of clinical trial sites ranging in size from the world’s largest institutions to individual practitioners. In fact, a single late-phase study could involve as many as 1,000 different investigators.

Today, most pharmaceutical sponsors identify and name their investigational products in their own unique way, using their own packaging and labelling. Although these products are usually serialised and barcoded, they do not comply with international standards.

At the other end of this supply chain is the clinical trial site, who faces the daunting challenge of managing hundreds of trials across multiple suppliers. Due to a lack of standardisation at the top of the supply chain, these trial sites find themselves having to manually re-label packages in an attempt to manage investigational products. The result is that many sites end up managing as many different systems as there are sponsors.

On clinical trials

1000

different investigators
involved in clinical trials

Hundreds of thousands of patients

can be impacted by each clinical trial

Tens of thousands

of research sites

Not only is this fragmented process expensive – it’s also potentially prone to errors. What the industry needs is a solution to consistently identify investigational products along the entire supply chain.

Implementing global standards is a good place to start.

What the industry needs is a solution to consistently identify investigational products along the entire supply chain. Implementing global standards is a good place to start.

An industry-led effort

Sixty representatives from 37 organisations came together to lend their expertise to developing such a standard. Representing the breadth of the clinical trial supply chain, this industry working group included pharmaceutical companies, hospitals, IT solution providers and contract researcher organizations and was chaired by CH Victor Dupouy, Pfizer and Sanofi.

What the industry group wanted was a global standard capable of enabling processes to work better across borders and around the world. Given its role as the most widely used standard for healthcare product identification and barcoding, the group chose to work with GS1. “Moving closer to the GS1 standard for identifying commercial pharmaceutical products seemed to CREAPHARM CS be the most consistent approach do this,” CREAPHARM CS Head of Innovation and Group Synergy, Development and IT Nicolas Le Rudulier.

Example of a product with a GS1
DataMatrix barcode

(01)09501101530003 - Global Trade Item Number

(10)AB-123 - Batch Number

(21)000124pc123 - Serial Number

(7240)PR0044 - Protocol Number

(01)09501101530003

(10)AB-123

(21)000124pc123

(7240)PR0044

Global standards unique to clinical trial products

The GS1 Application Standard for the Identification of Investigational Products in Clinical Trials defines the rules, roles, and responsibilities for the allocation of GS1 identification keys and the barcoding of investigational products, primarily from the time of kit assembly to use and, if necessary, destruction. It is intended for use by all parties involved in clinical trial processes, including: manufacturers, sponsors, packaging sites, distributors/3PLs, clinical trial sites, regulators, and patients.

“Because the sponsor is ultimately the owner of an investigational product and thus knows the product, they are best-positioned to identify it at the source – making it easier for everyone down the supply chain,” says GS1 Global Director of Healthcare Tania Snioch. “This is the basic premise of GS1 Standards.”

An element of trust

The advantages of using a standardised approach to labelling investigational products – accuracy, efficiency, process familiarity, and safety – become an across-the-board benefit that extends throughout the supply chain.

Most importantly, adopting the GS1 Standard adds an element of trust at all levels of the supply chain – a trust that ultimately extends to the patients themselves. And that’s something we can all get behind.

Adopting the GS1 Standard adds an element of trust at all levels of the supply chain – a trust that ultimately extends to the patients themselves.

Which of the following best describes the primary purpose of your visit?

Success

Thank you for your feedback!

Were you able to find the information you were looking for on our website?

Success

Thank you for your feedback!